Get Attractive Yield in Private Credit Within an ETF Wrapper

In the current extended higher-for-longer interest rate environment, income-focused investors face an ongoing challenge that involves finding attractive yields without taking on heavy credit risk. Traditional fixed income strategies have been exposed to additional uncertainty amid potential shifts in interest rate policy. That said, private credit has emerged as a resilient alternative. Supported by findings from BlackRock research, elevated base rates continue to power floating-rate direct lending strategies, which translate to elevated income generation well above realized credit losses.Key Takeaways: Private credit has emerged as a resilient income alternative in an extended higher-for-longer rate regime. It generates attractive yields well above realized credit losses while maintaining sound fundamental footing. Accessing private lending directly often carries multi-year lockups and tax reporting friction. This can complicate traditional portfolio allocations for both retail and institutional investors. The Simplify VettaFi Private Credit Strategy ETF (PCR) addresses these operational hurdles. Holding public BDCs and CEFs with daily ETF liquidity, it utilizes standard 1099 reporting and an active long/short total return swap hedge to buffer downside risk. See More: PCR ETF Offers Systematic Approach to Navigating Private CreditHealthy Credit Fundamentals and YieldDespite headwinds in the macroeconomic backdrop, BlackRock highlights that corporate credit fundamentals within direct lending remain structurally sound. Trailing 12-month realized losses in the Cliffwater Direct Lending Index remain below historical averages. This is notable even as borrower-specific conditions create selective pressure in sectors like software. Historically, private debt has delivered consistent yield over public market alternatives, which includes leveraged loans and traditional high-yield bonds. This yield premium reflects both lower secondary market liquidity as well as differentiated private sourcing opportunities. However, accessing private credit directly often introduces operational friction for standard retail and institutional portfolios, such as multi-year lockup periods, complex K-1 tax reporting, and high underlying fee structures. This is where exposure to a private credit ETF becomes ideal.PCR: Private Credit Access With Risk MitigationThe PCR ETF addresses the aforementioned operational hurdles by providing access to the private credit universe. PCR seeks a combination of monthly income and capital appreciation by investing in business development companies (BDCs) and publicly traded closed-end funds (CEFs) that directly finance middle-market private enterprises. By tracking the VettaFi Private Credit Index, PCR targets higher-yielding, lower-volatility securities across the private debt universe. Accordingly, PCR incorporates a layer of risk management designed to cushion against credit downturns. This is almost imperative in today’s fixed income environment. The fund deploys a proprietary derivative hedging strategy that utilizes long/short total return swaps on quality and junk equities to protect capital during market drawdowns and widening credit spreads. By combining liquid, publicly traded BDCs and CEFs with an active derivative hedge, PCR captures the yield advantages of private lending sans the traditional trade-offs. The ETF structure of PCR delivers daily liquidity, standard 1099 tax reporting, and lower operational overhead. Ultimately, this makes PCR an efficient vehicle for investors looking to boost portfolio cash flow while maintaining active risk controls. For more news, information, and analysis, visit the Institutional Income Strategies Content Hub. vettafi.com is owned by VettaFi LLC (“VettaFi”). VettaFi is the index provider for PCR, for which it receives an index licensing fee. However, PCR is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of PCR.